Northland Securities analyst Tim Chiang maintained a Buy rating on Amphastar Pharmaceuticals (AMPH) today and set a price target of $23.00. The company’s shares closed last Thursday at $16.95.
According to TipRanks.com, Chiang is ranked #4546 out of 6540 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amphastar Pharmaceuticals with a $23.00 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $23.06 and a one-year low of $12.33. Currently, Amphastar Pharmaceuticals has an average volume of 263.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets and distributes enoxaparin, cortrosyn, amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.
